Sintilimab plus anlotinib was demonstrated efficacy as second-line or later therapy for patients with PD-L1-positive advanced cervical cancer in a phase II trial, with an ORR of 54.8% (23/42) (75). This evidence concerns the gene CD274 and cervical cancer.